{
    "clinical_study": {
        "@rank": "142771", 
        "acronym": "AQUAMOD", 
        "arm_group": [
            {
                "arm_group_label": "ASAQ", 
                "arm_group_type": "Experimental", 
                "description": "In the intervention area,  obstetric, medical, drug-exposure histories will be collected at ANC visits. In addition, in the last trimester of the pregnancy (> 28 weeks of pregnancy), women will be systematically evaluated with RDT for whether they have malaria parasites and treated effectively. all malaria cases diagnosed in the 2nd and 3rd trimester in the intervention area will be treated with Amodiaquine + Artesunate (ASAQ)"
            }, 
            {
                "arm_group_label": "SP", 
                "arm_group_type": "No Intervention", 
                "description": "At ANC and labor wards for women in the control area, there will be no change from routine approaches. However, in case of malaria suspicion, a RDT detecting circulating P. falciparum antigens (SD Bioline) will be performed, if this is determined to be the most effective RDT (on the basis of current data and literature). If positive, the woman will be treated.  Treatment will consist on a full course of quinine (24 mg/kg/day for 7 days) as it is done routinely."
            }
        ], 
        "brief_summary": {
            "textblock": "The program's overall objective is to assess the impact of a package of interventions aimed\n      at reducing malaria-related mortality and morbidity in pregnant women and newborns by\n      ensuring access to a package of interventions designed to optimise the detection and\n      treatment of malaria during pregnancy as well as improving the early detection and treatment\n      of malaria during the third trimester."
        }, 
        "brief_title": "ANC & Malaria Diagnostic in Pregnancy", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Malaria", 
        "condition_browse": {
            "mesh_term": "Malaria"
        }, 
        "detailed_description": {
            "textblock": "This is a cluster-randomised study in which the health facility is the unit of\n      randomisation. 16 health facilities will be randomised to intervention and control. At the\n      community level women will be encouraged to access ANC early in the pregnancy, attend\n      follow-up antenatal visits throughout the pregnancy and deliver at the facility. The current\n      recommended standard of care will be provided to all women attending antenatal and obstetric\n      care. In the intervention area,  obstetric, medical, drug-exposure histories will be\n      collected at ANC visits. In addition, in the last trimester of the pregnancy (> 28 weeks of\n      pregnancy), women will be systematically evaluated with selected diagnostic test for whether\n      they have malaria parasites and treated effectively. Skilled birth attendants at the\n      facility will be trained in emergency obstetric and neonatal care and the assessment of\n      neonates for danger signs, low birth weight and external/observable birth defects. In the\n      control area, women will be provided with standard practice of care.  In both areas, women\n      will be diagnosed and treated at delivery if they are positive."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Located in the geographical location of Dafra & Do district\n\n          -  Have a minimum attendance of 200 pregnant women per year\n\n        Exclusion Criteria:\n\n          -  other public health facilities, private clinics and Dafra District Hospital will be\n             excluded from the study."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "50 Years", 
            "minimum_age": "16 Years"
        }, 
        "enrollment": {
            "#text": "7200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 8, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01703884", 
            "org_study_id": "B00531"
        }, 
        "intervention": {
            "arm_group_label": "ASAQ", 
            "description": "In the intervention area,  obstetric, medical, drug-exposure histories will be collected at ANC visits. In addition, in the last trimester of the pregnancy (> 28 weeks of pregnancy), women will be systematically evaluated with malaria RDT for whether they have malaria parasites and treated effectively with ASAQ.", 
            "intervention_name": "ASAQ", 
            "intervention_type": "Drug", 
            "other_name": "Coarsucam, ASAQ Winthrop"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Malria diagnosis", 
            "Malaria prevention in pregnancy", 
            "ANC services improvement"
        ], 
        "lastchanged_date": "October 10, 2012", 
        "location": {
            "contact": {
                "email": "kpodaherve@yahoo.fr", 
                "last_name": "Kpoda Herv\u00e9, MD, Msc", 
                "phone": "70304088", 
                "phone_ext": "226"
            }, 
            "facility": {
                "address": {
                    "city": "Bobo-Dioulasso", 
                    "country": "Burkina Faso", 
                    "state": "Hauts Bassins-houet", 
                    "zip": "01"
                }, 
                "name": "Dafra & Do districts"
            }, 
            "investigator": {
                "last_name": "Kpoda herv\u00e9, MD, Msc", 
                "role": "Sub-Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Burkina Faso"
        }, 
        "number_of_arms": "2", 
        "official_title": "Improved Quality of ANC and Diagnostic Services for Malaria in Pregnancy", 
        "other_outcome": [
            {
                "description": "The proportion of women with severe anaemia in women at delivery  (severe anaemia defined as Hg <8 g/dL),", 
                "measure": "The proportion of women with severe anaemia in women at delivery", 
                "safety_issue": "No", 
                "time_frame": "9 months"
            }, 
            {
                "description": "Low Birth Weight (defined as <2500g)", 
                "measure": "Low Birth Weight", 
                "safety_issue": "No", 
                "time_frame": "9 months"
            }, 
            {
                "description": "Stillbirth (defined as dead birth after 28 weeks of gestation)", 
                "measure": "Stillbirth", 
                "safety_issue": "No", 
                "time_frame": "28 weeks of gestation"
            }, 
            {
                "description": "Perinatal and early neonatal deaths (i.e. death within 7 days of birth)", 
                "measure": "Perinatal and early neonatal deaths", 
                "safety_issue": "No", 
                "time_frame": "7 days post delivery"
            }, 
            {
                "description": "Presence of external/observable birth defects in neonates identified at birth or as soon as possible thereafter.", 
                "measure": "External/observable birth defects", 
                "safety_issue": "No", 
                "time_frame": "9 months"
            }, 
            {
                "description": "Maternal death (death within 42 days of delivery, regardless of cause)", 
                "measure": "Maternal death", 
                "safety_issue": "No", 
                "time_frame": "42 days post delivery"
            }
        ], 
        "overall_contact": {
            "email": "tintohalidou@yahoo.fr", 
            "last_name": "Halidou Tinto, PharmD, PhD", 
            "phone": "70346354", 
            "phone_ext": "226"
        }, 
        "overall_contact_backup": {
            "email": "innocentvalea@yahoo.fr", 
            "last_name": "Innocent Valea, PharmD, Msc", 
            "phone": "70138271", 
            "phone_ext": "226"
        }, 
        "overall_official": {
            "affiliation": "centre muraz - irss", 
            "last_name": "Halidou Tinto, PharmD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Switzerland: World Health Organization / Tropical Disease Research (WHO/TDR)", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The main outcome variable of interest will be the proportion of women in each group with placental malaria at delivery (defined as placental biopsies positive for P. falciparum )", 
            "measure": "Placental malaria at delivery", 
            "safety_issue": "No", 
            "time_frame": "9 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01703884"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Centre Muraz", 
            "investigator_full_name": "Tinto Halidou", 
            "investigator_title": "PharmD, Msc, PhD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "The proportion of women with peripheral positive malaria infection at delivery (defined via detection of asexual stages of P. f alciparum by microscopy)", 
            "measure": "The proportion of women with peripheral positive malaria infection at delivery", 
            "safety_issue": "No", 
            "time_frame": "9 months"
        }, 
        "source": "Centre Muraz", 
        "sponsors": {
            "collaborator": {
                "agency": "World Health Organization", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Centre Muraz", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "October 2012"
    }
}